Clinical Trial Update: Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 exploratory study evaluated CD19-targeted CAR T cells (BZ019) in relapsed/refractory B-cell lymphomas, including diffuse large B-cell lymphoma and rel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Lymphoma

Drugs mentioned

• BZ019 (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Status: COMPLETED